Equity Profile

BIIB

Biogen Inc.

Health CareBiotechnology$28.8B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Biogen Inc. (BIIB) is a biotechnology company focused on developing therapies for neurological diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIIB Q2-2026 Earnings Preview

Context

Company Snapshot

Biogen Inc. (BIIB) is a biotechnology company focused on developing therapies for neurological diseases. With a market cap of $29 billion, it plays a significant role in the health care sector, particularly in addressing conditions like Alzheimer's and multiple sclerosis.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+16.70%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1-2026, Biogen reported an EPS of $3.57, beating estimates by 20.85%. The stock responded positively with a 6% increase the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are generally optimistic about Biogen's upcoming earnings, given its strong track record of beating EPS estimates in recent quarters.

Bull Case

If Biogen continues its trend of exceeding EPS estimates, it could lead to significant stock price appreciation, especially if accompanied by positive revenue growth.

Bear Case

Conversely, if Biogen fails to meet expectations or shows signs of declining revenue, it could lead to a sharp drop in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given Biogen's strong history of EPS surprises, this figure will be critical for investor sentiment and stock movement.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is essential for sustaining investor confidence and supporting stock price appreciation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Biogen's ability to maintain its EPS growth, particularly given its recent performance and potential new product launches.

Supporting Evidence

Biogen has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing in a larger move than historical averages, indicating potential for a surprise.

Insider buying activity suggests confidence in the company's future performance.

Key Risk

If Biogen's EPS comes in below $3.00, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Biogen can maintain its strong earnings trajectory amidst market challenges.

Bull Confirmed If

An EPS of $4.00 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $2.50 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.54%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant potential move for Biogen's stock following the earnings report, suggesting heightened investor uncertainty.

Options are pricing ±8.5% while BIIB has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.0%

Calls (21K)P/C Ratio: 0.58Puts (31K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Biogen beats expectations, history suggests a potential stock increase of around 1.44%, confirming the company's strong performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 0.12%, reflecting disappointment among investors.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Guidance on future EPS expectations and revenue growth.
4Insights into ongoing clinical trials and their potential outcomes.
5Discussion on cost management strategies and their effect on margins.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Biogen Inc. (BIIB) is a biotechnology company focused on developing therapies for neurological diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIIB Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+16.70%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1-2026, Biogen reported an EPS of $3.57, beating estimates by 20.85%. The stock responded positively with a 6% increase the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are generally optimistic about Biogen's upcoming earnings, given its strong track record of beating EPS estimates in recent quarters.

Bull Case

If Biogen continues its trend of exceeding EPS estimates, it could lead to significant stock price appreciation, especially if accompanied by positive revenue growth.

Bear Case

Conversely, if Biogen fails to meet expectations or shows signs of declining revenue, it could lead to a sharp drop in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given Biogen's strong history of EPS surprises, this figure will be critical for investor sentiment and stock movement.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is essential for sustaining investor confidence and supporting stock price appreciation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Biogen's ability to maintain its EPS growth, particularly given its recent performance and potential new product launches.

Supporting Evidence

Biogen has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing in a larger move than historical averages, indicating potential for a surprise.

Insider buying activity suggests confidence in the company's future performance.

Key Risk

If Biogen's EPS comes in below $3.00, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Biogen can maintain its strong earnings trajectory amidst market challenges.

Bull Confirmed If

An EPS of $4.00 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $2.50 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.54%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant potential move for Biogen's stock following the earnings report, suggesting heightened investor uncertainty.

Options are pricing ±8.5% while BIIB has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.0%

Calls (21K)P/C Ratio: 0.58Puts (31K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Biogen beats expectations, history suggests a potential stock increase of around 1.44%, confirming the company's strong performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 0.12%, reflecting disappointment among investors.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Guidance on future EPS expectations and revenue growth.
4Insights into ongoing clinical trials and their potential outcomes.
5Discussion on cost management strategies and their effect on margins.